Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

81.36 -0.68 (-0.83%)
Streaming Delayed Price Updated: 3:12 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
Webcast to be held Tuesday, January 6th at 8:00 a.m. ET 
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate in Upcoming Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Webcast to be held Monday, July 7th at 8:00 a.m. ET 
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
Webcast to be held Monday, March 3rd at 8:30 a.m. ET 
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate in Upcoming March Investor Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Agenda for Virtual R&D Day
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments 
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.